查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1596200

腎臟生物標記市場：按標記類型、檢測平台類型、應用和最終用戶 - 2025-2030 年全球預測

Renal Biomarkers Market by Marker Type (Blood Urea Nitrogen, Creatinine, Cystatin C), Assay Platform Type (Enzymatic Assay, Enzyme-Linked Immunosorbent Assay (ELISA), Turbidimetric Immunoassay), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年腎臟生物標記市場價值為13.3億美元，預計到2024年將達到14.3億美元，複合年成長率為7.72%，到2030年將達到22.4億美元。

腎臟生物標記是檢測腎功能和腎臟損傷的重要指標，為腎臟疾病的早期診斷和監測提供了一種非侵入性方法。由於慢性腎臟病(CKD) 和急性腎損傷 (AKI) 的盛行率不斷增加，對腎臟生物標記的需求產生了，早期檢測可以顯著改變疾病進展和患者預後。這些生物標記在臨床診斷、藥物開發和個人化治療計劃中具有廣泛的應用。最終用途廣泛，包括醫院、診斷實驗室和研究機構。影響腎臟生物標記市場的主要成長要素包括 CKD 和心血管疾病的增加、生物標記研究的技術進步以及醫療保健支出的增加。對個人化醫療的快速成長的需求以及基於人工智慧的分析在生物標記發現中的整合凸顯了巨大的商機。公司可以透過投資持續研發、策略聯盟和擴大產品系列，利用這些進步並有效捕捉市場潛力。

主要市場統計
基準年[2023] 13.3億美元
預測年份 [2024] 14.3億美元
預測年份 [2030] 22.4億美元
複合年成長率（%） 7.72%

然而，市場成長受到多種限制和挑戰的限制，包括生物標記發現和檢驗的高成本、監管障礙以及缺乏標準化程序。此外，新興國家有限的意識和基礎設施可能會帶來額外的挑戰。創新和研究的最佳領域包括開發具有更高特異性和敏感性的新型生物標記，探索用於綜合診斷的多生物標記組合，以及增強資料分析和預測能力的生物資訊學和人工智慧，例如技術投資。研究人員、生物製藥公司和監管機構需要共同努力，克服市場障礙並促進創新。市場競爭激烈，發展迅速，需要不斷適應新的科學考量和技術開拓。透過領先並應對成本和效率挑戰，公司可以推動成長並保持市場競爭力。

市場動態：快速發展的腎臟生物標記市場的關鍵市場洞察

供需的動態交互作用正在改變腎臟生物標記市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 人群中腎功能損害的盛行率不斷增加
    • 加強意識提升
    • 個人化藥物和標靶治療的發展趨勢
  • 市場限制因素
    • 與腎臟生物標記相關的高成本
  • 市場機會
    • 積極研究引入新的腎臟生物標記
    • 腎臟手術新技術進展
  • 市場挑戰
    • 對生物標記失敗的擔憂

波特五力：駕馭腎臟生物標記市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解腎臟生物標記市場的外部影響

外部宏觀環境因素在塑造腎臟生物標記市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解腎臟生物標記市場的競爭格局

腎臟生物標記市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣腎臟生物標記市場供應商的績效評估

FPNV定位矩陣是評估腎臟生物標記市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製腎臟生物標記市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對腎臟生物標記市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人群中腎臟病盛行率上升
      • 加強提高人們對腎臟疾病和腎臟生物標記的認知
      • 個人化藥物和標靶治療的發展趨勢
    • 抑制因素
      • 與腎臟生物標記相關的高成本
    • 機會
      • 大力研究引入新的腎臟生物標記
      • 腎臟手術新技術進展
    • 任務
      • 對生物標記失敗的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第 6 章按標記類型分類的腎臟生物標記市場

  • 血中尿素氮
  • 肌酸酐
  • Cystatin C
  • 嗜中性白血球明膠酶相關脂質運載蛋白

第 7 章按檢測平台類型分類的腎臟生物標記市場

  • 酵素測定
  • 酵素免疫分析法測定法 (ELISA)
  • 免疫檢測

第8章腎臟生物標記市場：依應用分類

  • 疾病進展的診斷和監測
  • 調查

第 9 章 腎臟生物標記市場：依最終用戶分類

  • 診斷實驗室
  • 醫院

第10章美洲腎臟生物標記市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區腎臟生物標記市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的腎臟生物標記市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • BioPorto Diagnostics A/S
  • Cipla Limited
  • Danaher Corporation
  • DiaSorin SpA
  • Eli Lilly and Co
  • Enzo Biochem, Inc.
  • Eurofins Viracor Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Novartis AG
  • Novatein Biosciences Inc.
  • PerkinElmer Inc.
  • Randox Laboratories Ltd.
  • Renalytix AI PLC
  • Sanofi-Aventis, LLC.
  • Sekisui Diagnostics, LLC
  • Siemens Healthineers AG
  • SphingoTec GmbH
  • Thermo Fisher Scientific Inc.
Product Code: MRR-521BAA36EA84

The Renal Biomarkers Market was valued at USD 1.33 billion in 2023, expected to reach USD 1.43 billion in 2024, and is projected to grow at a CAGR of 7.72%, to USD 2.24 billion by 2030.

Renal biomarkers are critical indicators used to detect kidney function and damage, offering a non-invasive method for early diagnosis and monitoring of renal diseases. The necessity for renal biomarkers arises from the growing prevalence of chronic kidney diseases (CKD) and acute kidney injuries (AKI), where early detection can significantly alter disease progression and patient outcomes. These biomarkers are applied extensively across clinical diagnostics, drug development, and personalizing treatment plans. The end-use spans across hospitals, diagnostic laboratories, and research institutions. Key growth factors influencing the renal biomarker market include the rising incidences of CKD and cardiovascular diseases, technological advancements in biomarker research, and increased healthcare expenditure. The burgeoning demand for personalized medicine and the integration of AI-based analytics in biomarker discovery highlight substantial opportunities. Companies can leverage these advancements by investing in continuous R&D, strategic collaborations, and expanding their product portfolios to capture the market potential effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 1.33 billion
Estimated Year [2024] USD 1.43 billion
Forecast Year [2030] USD 2.24 billion
CAGR (%) 7.72%

However, market growth is restricted by several limitations and challenging factors such as the high costs of biomarker discovery and validation, regulatory hurdles, and the lack of standardized procedures. Furthermore, limited awareness and infrastructure in emerging economies may pose additional challenges. The best areas for innovation and research include developing novel biomarkers with higher specificity and sensitivity, exploring multi-biomarker panels for comprehensive diagnosis, and investing in bioinformatics and AI technologies to enhance data analysis and prediction capabilities. There's a need for collaborative efforts between researchers, biopharma companies, and regulatory bodies to overcome market barriers and expedite innovation. The nature of the market is highly competitive, characterized by rapid advancements, and requires continuous adaptation to new scientific insights and technological developments. By staying ahead in innovation and addressing the challenges of cost and efficiency, businesses can drive growth and maintain a competitive edge in the renal biomarkers market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Renal Biomarkers Market

The Renal Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of renal disorders among population
    • Growing initiatives to create awareness on renal diseases and renal biomarkers
    • Trend towards developing personalized medicines and targeted therapies
  • Market Restraints
    • High costs associated with renal biomarkers
  • Market Opportunities
    • Robust research activities to introduce new renal biomarkers
    • Emerging technological advancements in renal surgeries
  • Market Challenges
    • Concerns over failure of biomarkers

Porter's Five Forces: A Strategic Tool for Navigating the Renal Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Renal Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Renal Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Renal Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Renal Biomarkers Market

A detailed market share analysis in the Renal Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Renal Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Renal Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Renal Biomarkers Market

A strategic analysis of the Renal Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Renal Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, Bio-Rad Laboratories, Inc., bioMerieux SA, BioPorto Diagnostics A/S, Cipla Limited, Danaher Corporation, DiaSorin S.p.A., Eli Lilly and Co, Enzo Biochem, Inc., Eurofins Viracor Inc., F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Novartis AG, Novatein Biosciences Inc., PerkinElmer Inc., Randox Laboratories Ltd., Renalytix AI PLC, Sanofi-Aventis, LLC., Sekisui Diagnostics, LLC, Siemens Healthineers AG, SphingoTec GmbH, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Renal Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Marker Type, market is studied across Blood Urea Nitrogen, Creatinine, Cystatin C, and Neutrophil Gelatinase-Associated Lipocalin.
  • Based on Assay Platform Type, market is studied across Enzymatic Assay, Enzyme-Linked Immunosorbent Assay (ELISA), and Turbidimetric Immunoassay.
  • Based on Application, market is studied across Diagnosis & Disease Progression Monitoring and Research.
  • Based on End-User, market is studied across Diagnostic Laboratories and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of renal disorders among population
      • 5.1.1.2. Growing initiatives to create awareness on renal diseases and renal biomarkers
      • 5.1.1.3. Trend towards developing personalized medicines and targeted therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with renal biomarkers
    • 5.1.3. Opportunities
      • 5.1.3.1. Robust research activities to introduce new renal biomarkers
      • 5.1.3.2. Emerging technological advancements in renal surgeries
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns over failure of biomarkers
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Renal Biomarkers Market, by Marker Type

  • 6.1. Introduction
  • 6.2. Blood Urea Nitrogen
  • 6.3. Creatinine
  • 6.4. Cystatin C
  • 6.5. Neutrophil Gelatinase-Associated Lipocalin

7. Renal Biomarkers Market, by Assay Platform Type

  • 7.1. Introduction
  • 7.2. Enzymatic Assay
  • 7.3. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 7.4. Turbidimetric Immunoassay

8. Renal Biomarkers Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnosis & Disease Progression Monitoring
  • 8.3. Research

9. Renal Biomarkers Market, by End-User

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals

10. Americas Renal Biomarkers Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Renal Biomarkers Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Renal Biomarkers Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. BioPorto Diagnostics A/S
  • 7. Cipla Limited
  • 8. Danaher Corporation
  • 9. DiaSorin S.p.A.
  • 10. Eli Lilly and Co
  • 11. Enzo Biochem, Inc.
  • 12. Eurofins Viracor Inc.
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Fresenius Kabi AG
  • 15. Novartis AG
  • 16. Novatein Biosciences Inc.
  • 17. PerkinElmer Inc.
  • 18. Randox Laboratories Ltd.
  • 19. Renalytix AI PLC
  • 20. Sanofi-Aventis, LLC.
  • 21. Sekisui Diagnostics, LLC
  • 22. Siemens Healthineers AG
  • 23. SphingoTec GmbH
  • 24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. RENAL BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. RENAL BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RENAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. RENAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. RENAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RENAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RENAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RENAL BIOMARKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY BLOOD UREA NITROGEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY CREATININE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY CYSTATIN C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ENZYMATIC ASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY TURBIDIMETRIC IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY DIAGNOSIS & DISEASE PROGRESSION MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. RENAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. RENAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023